Skip to main navigation
AC Immune - World-class science that makes a difference in  patients' lives
  • About Us
    About us Our Teams Our Partners Our R&D Strategy
  • Our Science
    Our Science Pioneering Precision Medicine Technology Platforms Scientific Publications
  • Our Pipeline
    Our Pipeline Therapeutic Focus Clinical Trials
  • Investors
  • Careers
    Careers Join us
Investors
  • Why Invest
  • Key Figures
  • Share Price
  • Analyst Coverage
  • Milestones
  • Key Shareholders
  • FAQ
  • Contacts & Resources
Press Releases
In the News
Events & Presentations
Corporate Governance
Financial Reporting
Annual Reports
search

Press Releases

  1. Home
  2. Investors
  3. Press Releases

PRESS RELEASES

 
Date Title View
Mar 20, 2023 AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
Mar 16, 2023 AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
Mar 08, 2023 AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
Feb 07, 2023 AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
Feb 02, 2023 AC Immune to Present at the SVB Securities Global Biopharma Conference
Jan 26, 2023 AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
Jan 18, 2023 AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease

Shareholder Tools

Print Page
Print Page
Email Alerts
Email Alerts
Information Request
Information Request
Contact IR
Contact IR

AC Immune SA

EPFL Innovation Park-Building B 1015 Lausanne / Switzerland
  • Phone: +41 21 345 91 21
  • Fax: +41 21 345 91 20
  • Email: info@acimmune.com
  • Home
  • About Us
  • Our Science
  • Our Pipeline
  • Investors
  • Careers

Stay in touch

Get to know us

Social Links (Redesign)

© 2023 AC Immune SA

Legal Links (Redesign)

  • Privacy policy
  • Supplier information
  • Terms of use